- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02749864
Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP) (PREVHEP)
Personalized Medicine in HCV Infection. A Prospective, Multicenter, Epidemiological Study to Evaluate the Prevalence of Hepatitis C Infection in Spain in 2015 (PREVHEP)
The hypothesis of this investigation stresses that the current understanding of the prevalence of HCV infection in the general population and in different subgroups will serve to lay out medium- and long-term measures for action geared toward reducing the disease burden through preventive, research, screening and therapeutic measures.
Aim: To determine the prevalence of seropositivity and chronic infection with the HCV and to analyze the associated factors. To analyze and infer different screening strategies for HCV infection based on the at-risk groups/cohorts of elevated prevalence detected. to assess the efficiency of screening strategies and the subsequent cost-effectiveness of treatment in the general population
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Design of the study: Seroepidemiological and virological study of cross-sectional population-based.
Patients and sampling: The study population has been distributed in groups according to age (20-34; 35-49; 50-74 years) and sex. In order to select a representative sample of this overall population, three Spanish regions will be selected on the basis of their different HCV-related hospitalisation rates defined as follows: high, >120 cases/100,000 inhabitants (Madrid); medium, 90-119 cases/100,000 inhabitants (Cantabria); or low, <90 cases/100,000 inhabitants (Valencia).
The participants will be selected through a random, representative sample using our two-stage conglomerate sampling with stratification of the First-Stage Units. These FSUs are made up by the Basic Health Areas (Health Centers). The Second-Stage Units are made up by the individuals. The stratification criteria used in the first stage will be the socioeconomic status-rural/urban environment. The selection of sample elements will be carried out through simple random sampling from the healthcare card database pertaining to the selected Health Centers. A sequence of random, computer-generated numbers will be obtained.
Sample size: In order to achieve an accuracy of 0.4% in the estimate of a percentage through a two-tailed 95% confidence interval, assuming the prevalences indicated by age strata in the general Spanish population (0.6%, 1.9% and 2.7% respectively), a total of 12,263 subjects distributed as follows: 1,456 aged 20-34 years, 4,476 aged 35-49 years and 6,331 aged 50-74 years.
Anticipating an uptake of 9-15%,21 following invitation via telephone, between 81,753 and 136,255 subjects distributed over the three regions needed to be contacted at random.
Recruitment method for randomized patients. Selected subjects will be called by phone by trained personnel. The subject will be invited to report for an interview in order to carry out a socio-healthcare questionnaire, a physical examination, and an analytical test. In the event the patient refuses to participate, permission shall be requested to collect minimum anonymous data for the subsequent study of possible screening biases. Patients meeting inclusion criteria and provide written informed consent to be included in the study.
Variables in the study: socio-healthcare questionnaire includes variables such as age, sex, socioeconomic status, risk factors, health habits, etc. Analytical variables (blood count, biochemistry, serologies for HBV and HCV, etc.) are collected. A Fibroscan is also performed. A cost-effectiveness of screening strategies and treatment will be analysed using a Markov model
Full duration: 21 months
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Madrid, Spanien, 28222
- Hospital Universitario Puerta de Hierro-Majadahonda
-
-
Cantabria
-
Santander, Cantabria, Spanien, 39008
- Hospital Universitario Marques de Valdecilla
-
-
Comunidad Valenciana
-
Valencia, Comunidad Valenciana, Spanien
- Hospital Clínico Universitario de Valencia
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
General population aged 20-74 years who agree to participate when contacted by phone call after a two-stage conglomerate sampling with stratification of the First-Stage Units.
The study will be carried out in three Autonomous Communities (regions) in Spain.
Beschreibung
Inclusion Criteria:
- Patients between 20 and 74 who have health card in each of the autonomous communities studied.
- They agree to participate, understand and give informed consent.
Exclusion Criteria:
- Do not meet the criteria above.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
---|
A: Age 20-34 yr
No intervention Cohort of subjects aged 20-34 years old.
|
B: Age 35-49 yr
No intervention Cohort of subjects aged 35-49 years old.
|
C: Age 50-79 yr
No intervention Cohort of subjects aged 50-79 years old.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Serum Anti-HCV
Zeitfenster: 1 day
|
Anti-HCV seroprevalence
|
1 day
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
HCV RNA viral load
Zeitfenster: 1 day
|
Chronic HCV infection
|
1 day
|
Serum HBsAg
Zeitfenster: 1 day
|
HBV portador status
|
1 day
|
Birth date
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Sex
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Nationality
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Residence time in Spain
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Educational level
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Activity and professional qualifications
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Lifestyle habit/risk factor score
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Nosocomial risk score
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
History of previous check of HCV/HBV exposure
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Sexual behaviour
Zeitfenster: 1 day
|
Questionnarie about socio-economic and Health variables
|
1 day
|
Number of sexual partners
Zeitfenster: 1 day
|
Questionnaire about socio-economic and Health variables
|
1 day
|
Weight (kg)
Zeitfenster: 1 day
|
Weight (Anthropometric variables)
|
1 day
|
Height (cm)
Zeitfenster: 1 day
|
Height (Anthropometric variables)
|
1 day
|
BMI
Zeitfenster: 1 day
|
Body Mass Index (Anthropometric variables)
|
1 day
|
Abdominal perimeter (cm)
Zeitfenster: 1 day
|
Abdominal perimeter (Anthropometric variables)
|
1 day
|
Waist perimeter (cm)
Zeitfenster: 1 day
|
Waist perimeter (Anthropometric variables)
|
1 day
|
Blood pressure (mmHg)
Zeitfenster: 1 day
|
Blood pressure
|
1 day
|
ALT
Zeitfenster: 1 day
|
Liver function tests
|
1 day
|
AST
Zeitfenster: 1 day
|
Liver function tests
|
1 day
|
Alkaline Phosphatase (AP)
Zeitfenster: 1 day
|
Liver function tests
|
1 day
|
GGT (Gammaglutamyl transferase)
Zeitfenster: 1 day
|
Liver function tests
|
1 day
|
Bilirubin
Zeitfenster: 1 day
|
Liver function tests
|
1 day
|
Serum Albumin
Zeitfenster: 1 day
|
Biochemistry parameters
|
1 day
|
Total Cholesterol
Zeitfenster: 1 day
|
Biochemistry parameters
|
1 day
|
LDL Cholesterol
Zeitfenster: 1 day
|
Biochemistry parameters
|
1 day
|
HDL Cholesterol
Zeitfenster: 1 day
|
Biochemistry parameters
|
1 day
|
Triglycerides
Zeitfenster: 1 day
|
Biochemistry parameters
|
1 day
|
White blood cell count (WBC or leukocyte count)
Zeitfenster: 1 day
|
CBC
|
1 day
|
Hemoglobin
Zeitfenster: 1 day
|
CBC
|
1 day
|
Platelets
Zeitfenster: 1 day
|
CBC
|
1 day
|
INR
Zeitfenster: 1 day
|
International Normalized Ratio
|
1 day
|
kPa in Fibroscan
Zeitfenster: 1 day
|
Liver stiffness
|
1 day
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Javier Crespo García, MDPhD, Head of Gastroenterology and Hepatology at Hospital Universitario Marqués de Valdecilla. Professor at the Universidad de Cantabria
- Hauptermittler: Jose L Calleja, MDPhD, Head of Gastroenterology and Hepatology at Hospital Universitario Puerta de Hierro-Majadahonda
- Hauptermittler: Miguel A Serra, MDPhD, Gastroenterology and Hepatology Department at Hospital Clínico U. de Valencia
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012 May;55(5):1344-55. doi: 10.1002/hep.25510. Epub 2012 Mar 18.
- Bruguera M, Forns X. [Hepatitis C in Spain]. Med Clin (Barc). 2006 Jun 17;127(3):113-7. doi: 10.1157/13090276. Spanish.
- Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, Luma HN, Charlton M. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014 Apr;60(4):691-8. doi: 10.1016/j.jhep.2013.11.014. Epub 2013 Nov 27.
- Llop E, Iruzubieta P, Perello C, Fernandez Carrillo C, Cabezas J, Escudero MD, Gonzalez M, Hernandez Conde M, Puchades L, Arias-Loste MT, Serra MA, Crespo J, Calleja JL. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. United European Gastroenterol J. 2021 Oct;9(8):892-902. doi: 10.1002/ueg2.12109. Epub 2021 Jun 2.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Hepadnaviridae-Infektionen
- DNA-Virusinfektionen
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis C
Andere Studien-ID-Nummern
- JCG-PREVHEP-2015-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNoch keine Rekrutierung
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRekrutierungChronische Hepatitis b | Zirrhose durch Hepatitis BChina
-
Nanfang Hospital of Southern Medical UniversityRekrutierung
-
IlDong Pharmaceutical Co LtdRekrutierungChronische Hepatitis bKorea, Republik von
-
Antios Therapeutics, IncBeendetChronische Hepatitis bVereinigte Staaten
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unbekannt
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnbekanntChronische Hepatitis b
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi Hospital... und andere MitarbeiterRekrutierungPatienten mit chronischer Hepatitis b stellen nach Absetzen des Nukleosidanalogs auf tAf um (CHANGE)Chronische Hepatitis b | Hepatitis-B-ReaktivierungTaiwan
-
Mahidol UniversityUnbekanntChronische Hepatitis B, HBsAg, Hepatitis-B-ImpfstoffThailand
-
Tongji HospitalGilead SciencesRekrutierung